Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07832643
Recruiting Not applicable

Primary Allergy and Its Impact on the Occurrence of Respiratory Distress in Infants at 12 Months of Age

NCT07832643 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-07-01
Last updated
2026-09-22

Condition(s) studied

AllergyRespiratory DistressAtopic ManifestationsImmediate Postnatal Parameters

Investigational drug(s) / intervention(s)

questionnaire

questionnaire: questionnaire will be emailed when the child is 6 months old and again when the child is 12 months old. These questionnaires include questions about any health issues that have arisen since the last contact, the number and reason for the child's hospitalizations (if applicable), the child's vaccinations, and the child's diet.

Study summary

The number of people with allergies has been steadily increasing over the years. Symptoms in infants, such as bronchiolitis, gastroesophageal reflux, eczema, or atopic dermatitis, can be early warning signs of allergies in childhood. Given the rising prevalence of allergies and the number of children affected by bronchiolitis, it is worth investigating whether the presence of allergies in parents is associated with a higher likelihood of developing bronchiolitis in childhood.

To determine the incidence of respiratory distress in infants with at least one allergic parent compared to infants with no allergic parents at 12 months of age.

Parents will be asked to complete a questionnaire at two time points: at 6 months and at 12 months of age.

The incidence of bronchiolitis during the first year of life is higher among infants with at least one parent who has allergies.

Eligibility

Sex
ALL
Min age
—
Max age
1 Year
Healthy volunteers
No
Inclusion Criteria: * Newborns delivered at Amiens Picardie University Hospital, Full-term newborns, i.e., * ≥ 37+0 weeks of gestation (SA), * Newborns whose mothers are of legal age and capable of understanding, reading, and speaking French or, failing that, who have someone in their immediate circle capable of understanding, reading, and speaking French; * Newborns whose mothers are enrolled in the social security system; Exclusion Criteria: * Premature newborns * Newborns whose parents refused to allow them to participate in the study * Newborns from multiple pregnancies * Newborns with malformations diagnosed prenatally or immediately after birth (in the delivery room)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHU Amiens Picardie Amiens Picardie Recruiting

More Centre Hospitalier Universitaire, Amiens trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07832643 on ClinicalTrials.gov ↗ ← All trials in France